Clinical trials: Renal Cell Carcinoma (Kidney Cancer)
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00053209
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 121 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Kidney Cancer
Bortezomib in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276614
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Kidney Cancer
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01164228
- Testing
- Gemcitabine, Sunitinib
- Where
- 99 sites in United States
- Volunteers
- 87 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014144
- Testing
- gefitinib
- Where
- 95 sites in United States
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Renal Cell Carcinoma, Kidney Cancer
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma.
- Trial name
- NCT00496587
- Testing
- Capecitabine, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Renal Cell Carcinoma
1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
The main purpose of this study is to find out how useful dovitinib is when given as the initial treatment to participants with advanced kidney cancer, that has spread to other parts of the body.
- Trial name
- DILIGENCE-1 (NCT01791387)
- Testing
- Dovitinib
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Auckland District Health Board
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma, Hypertension
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel…
- Conditions
- Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
- Trial name
- NCT03709771
- Testing
- Ambulatory Blood Pressure Measurement
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Healthy
The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients
In this prospective pharmacokinetic we investigate the following topics: The influence of grapefruit juice and orange juice on the steady-state pharmacokinetics of sunitinib in cancer patients The influence of sunitinib on the…
- Trial name
- NCT01743300
- Testing
- Sunitinib, Midazolam, Orange juice
- Volunteers
- 15 people
- Sponsor
- Leiden University Medical Center
Renal Cell Cancer
An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma
This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma.
- Trial name
- NCT01351571
- Where
- 2 sites in India
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Prostate Cancer, Stage I Renal Cell Cancer
- Trial name
- NCT02767921
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Radical Cystectomy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Kidney Cancer
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2).
- Trial name
- RESTRICT (NCT04922307)
- Testing
- Blood Sparing Protocol, Standard Blood Replacement
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vanderbilt University Medical Center
Carcinoma, Renal Cell
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.
- Trial name
- NCT00043407
- Testing
- CPG 7909
- Volunteers
- 42 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic advanced renal cancer. Blood samples will also be collected for research purposes.
- Trial name
- NCT02867332
- Testing
- PD-1 Knockout T Cells, Cyclophosphamide, IL-2
- Sponsor
- Peking University
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the…
- Trial name
- NCT00041106
- Testing
- gemcitabine hydrochloride, cisplatin, gefitinib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma
Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC
This study is being conducted to test whether an imaging technique called a "piflufolastat F 18 PET/CT" imaging scan can be used to diagnose and describe the extent of clear cell Renal Carcinoma in patients.
- Trial name
- HARRIER (NCT07084909)
- Testing
- piflufolastat F 18
- Where
- 2 sites in United States
- Sponsor
- Lantheus Medical Imaging
Kidney Cancer
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00853021
- Testing
- aldesleukin, bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jorge A. Garcia, MD